Form 4: Cingulate Inc. SVP and CFO Jennifer L. Callahan Granted Stock Options

Jennifer L. Callahan, SVP and CFO of Cingulate Inc., was granted stock options for 94,986 shares on June 11, 2024, as disclosed in a Form 4 filing with the SEC.

Summary

• On June 13, 2024, a Form 4 filing with the SEC disclosed that Jennifer L. Callahan, SVP and CFO of Cingulate Inc., was granted stock options.
• The stock option grant, approved by Cingulate Inc.'s board of directors on March 4, 2024, was contingent upon stockholder approval of Amendment No. 1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan, which was obtained on June 11, 2024.
• Callahan was granted options to purchase 94,986 shares of Cingulate Inc. common stock at an exercise price of $1.18 per share.
• The options vest with 50% vesting six months from the grant date and the remaining shares vesting in substantially equal monthly installments over the subsequent 30-month period.
• The options expire on March 4, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a standard executive compensation practice that aligns management interests with shareholders.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Form 4, Cingulate Inc., Jennifer L. Callahan, executive compensation, insider trading